Differences In Specific Binding Research Articles

New Repeat Polymorphism in the AKT1 Gene Predicts Striatal Dopamine D2/D3 Receptor Availability and Stimulant-Induced Dopamine Release in the Healthy Human Brain.

The role of the protein kinase Akt1 in dopamine neurotransmission is well recognized and has been implicated in schizophrenia and psychosis. However, the extent to which variants in the AKT1 gene influence dopamine neurotransmission is not well understood. Here we investigated the effect of a newly characterized variant number tandem repeat (VNTR) polymorphism in AKT1 [major alleles: L- (eight repeats) and H- (nine repeats)] on striatal dopamine D2/D3 receptor (DRD2) availability and on dopamine release in healthy volunteers. We used PET and [11C]raclopride to assess baseline DRD2 availability in 91 participants. In 54 of these participants, we also measured intravenous methylphenidate-induced dopamine release to measure dopamine release. Dopamine release was quantified as the difference in specific binding of [11C]raclopride (nondisplaceable binding potential) between baseline values and values following methylphenidate injection. There was an effect of AKT1 genotype on DRD2 availability at baseline for the caudate (F(2,90) = 8.2, p = 0.001) and putamen (F(2,90) = 6.6, p = 0.002), but not the ventral striatum (p = 0.3). For the caudate and putamen, LL showed higher DRD2 availability than HH; HL were in between. There was also a significant effect of AKT1 genotype on dopamine increases in the ventral striatum (F(2,53) = 5.3, p = 0.009), with increases being stronger in HH > HL > LL. However, no dopamine increases were observed in the caudate (p = 0.1) or putamen (p = 0.8) following methylphenidate injection. Our results provide evidence that the AKT1 gene modulates both striatal DRD2 availability and dopamine release in the human brain, which could account for its association with schizophrenia and psychosis. The clinical relevance of the newly characterized AKT1 VNTR merits investigation.SIGNIFICANCE STATEMENT The AKT1 gene has been implicated in schizophrenia and psychosis. This association is likely to reflect modulation of dopamine signaling by Akt1 kinase since striatal dopamine hyperstimulation is associated with psychosis and schizophrenia. Here, using PET with [11C]raclopride, we identified in the AKT1 gene a new variable number tandem repeat (VNTR) marker associated with baseline striatal dopamine D2/D3 receptor availability and with methylphenidate-induced striatal dopamine increases in healthy volunteers. Our results confirm the involvement of the AKT1 gene in modulating striatal dopamine signaling in the human brain. Future studies are needed to assess the association of this new VNTR AKT1 variant in schizophrenia and drug-induced psychoses.

Reference tissue modeling with parameter coupling: application to a study of SERT binding in HIV

When applicable, it is generally preferred to evaluate positron emission tomography (PET) studies using a reference tissue-based approach as that avoids the need for invasive arterial blood sampling. However, most reference tissue methods have been shown to have a bias that is dependent on the level of tracer binding, and the variability of parameter estimates may be substantially affected by noise level. In a study of serotonin transporter (SERT) binding in HIV dementia, it was determined that applying parameter coupling to the simplified reference tissue model (SRTM) reduced the variability of parameter estimates and yielded the strongest between-group significant differences in SERT binding. The use of parameter coupling makes the application of SRTM more consistent with conventional blood input models and reduces the total number of fitted parameters, thus should yield more robust parameter estimates. Here, we provide a detailed evaluation of the application of parameter constraint and parameter coupling to [11C]DASB PET studies. Five quantitative methods, including three methods that constrain the reference tissue clearance (kr2) to a common value across regions were applied to the clinical and simulated data to compare measurement of the tracer binding potential (BPND). Compared with standard SRTM, either coupling of kr2 across regions or constraining kr2 to a first-pass estimate improved the sensitivity of SRTM to measuring a significant difference in BPND between patients and controls. Parameter coupling was particularly effective in reducing the variance of parameter estimates, which was less than 50% of the variance obtained with standard SRTM. A linear approach was also improved when constraining kr2 to a first-pass estimate, although the SRTM-based methods yielded stronger significant differences when applied to the clinical study. This work shows that parameter coupling reduces the variance of parameter estimates and may better discriminate between-group differences in specific binding.

Increased Epidermal Growth Factor Receptor Expression in Rat Aorta in Deoxycorticosterone Acetate-Salt Induced Hypertension/ATL>

79 Receptors and signal transduction Epidermal growth factor (EGF) causes contraction in arteries from Deoxycorticosterone Acetate-Salt (DOCA) hypertensive rats but not in normotensive sham rats. We hypothesized that an increase in the number of EGF receptors (EGFR) in arteries from DOCA-salt rats enables the observed contraction to EGF to occur. All DOCA-salt rats had a systolic blood pressure (SBP) > 170 mm Hg, while all sham rats had a SBP < 135 mm Hg. Thoracic aorta were removed for measurement of isometric force, EGFR mRNA levels, and EGFR protein levels. EGF caused a significant contraction in endothelium-denuded aorta from DOCA-salt rats [(35 +/- 3% of maximal phenylephrine (PE, 10uM)-induced contraction)] as compared to aorta from sham rats (4+/-2%). EGFR tyrosine kinase specific inhibitors, 4,5-Dianilinophthalimide (10uM) and AG1478 (250 nM), reduced the contraction in aorta from DOCA-salt rats by 85 +/- 14% and 65+/- 10% respectively. The mRNA for EGFR in DOCA-salt aorta was increased 4.2 fold as compared to sham aorta. EGFR protein levels were examined using immunohistochemistry where specific binding was defined as binding which was quenched by a 10x concentration of neutralizing peptide. In 7 of 8 quantitative comparisons between aorta from DOCA-salt and sham rats, DOCA-salt aorta sections demonstrated greater specific binding than in sections of sham aorta. In the 7 positive comparisons, the difference in specific binding between DOCA-salt and sham sections ranged from 2.31 to 20.67 gray scale units (gsu) with an average of 9.18 gsu (figure). An increase in specific binding in aorta from DOCA-salt rats suggests the vessels have more EGFR that could facilitate the enhanced contractility to EGF in DOCA-salt aorta.

Immunochemical studies on the putative plasmalemmal receptor for 1,25-dihydroxyvitamin D 3: Ii. chick kidney and brain

Chick kidney and brain were analyzed for the subcellular distribution (if any) of a putative plasma membrane receptor for 1,25-dihydroxyvitamin D 3 [1,25(OH) 2D 3]. Fractionation protocols were found to be based not only on differential centrifugation conditions, but also gentleness of resuspension procedures, and sufficiently dense Percoll gradients. The postnuclear pellets were resolved on 21.85% Percoll gradients overlayed on 2.4 M sucrose cushions. For both kidney and brain, fraction 1 (bottom of tube) was found to be enriched over whole homogenate 5.4- and 1.6-fold, respectively, in acid phosphatase activity, fractions 2 through 5 were enriched four- and eightfold, respectively, in succinate dehydrogenase activity, fraction 8 contained Golgi, as judged by a small peak of α-mannosidase activity, and fraction 9 was enriched sevenfold (for each tissue) in Na +,K +-ATPase activity. Western analyses, using a characterized antibody to the putative chick intestinal plasma membrane vitamin D receptor, revealed the highest levels of antigenicity in both chick kidney and brain in plasma membrane and Golgi fractions, followed by unidentified membranes in fractions 6 and 7 of Percoll gradients. Distribution of specific binding of [ 3H]1,25(OH) 2D 3 in Percoll gradient fractions paralleled that of antigenicity. Qualitatively, kidney plasma membrane contained more antigen than brain plasma membrane after Western blot analyses; these results were mirrored by differences in specific binding of the tritiated secosteroid (65 ± 14.5 and 34 ± 11.9 fmol/mg of protein, respectively).

Increased specific binding of insulin‐like growth factor‐I in healing cutaneous wounds

Insulin-like growth factor-I is a polypeptide hormone structurally related to insulin. It is a potent mitogen that promotes growth and differentiation in many tissues. A role for insulin-like growth factor-I in wound healing is suggested by its rapid rise in levels and increased insulin-like growth factor-I messenger RNA expression in tissue after wounding. We designed our study to characterize possible changes in insulin-like growth factor-I receptor binding during wound healing. Surgical wounds created on the abdominal skin of anesthetized New Zealand White rabbits were either left open or closed primarily. Size- and weight-matched specimens were harvested at wounding time (day 0), and at 1, 4, 7, 38, and 50 days after wounding. Preliminary experiments showed that the greatest difference in specific binding occurred between day 0 and day 7. (125)I-insulin-like growth factor-I binding studies were performed on frozen tissue specimens and autoradiography was performed and analyzed by computerized densitometry. Scatchard analysis of the binding data showed a single class of insulin-like growth factor-I binding sites whose affinity that is, binding constant (K(d) = 0.6 x 10(-9)) did not change significantly over time; in contrast there was a threefold increase in the number of receptors per milligram tissue in day 7 wound tissue versus normal skin harvested at day 0 (17.3 +/- 2.6 x 10(10) versus 4.7 +/- 2.5 x 10(10), respectively, p < 0.05). Binding inhibition experiments showed that (125)I-insulin-like growth factor-I binding was most specific to insulin-like growth factor-I with insulin-like growth factor-I > insulin-like growth factor-II > insulin. This increase in binding was due to upregulation of insulin-like growth factor-I receptors rather than increased levels of insulin-like growth factor-I binding protein as less than 20% of the threefold increase in binding at day 7 could be attributed to insulin-like growth factor-I binding protein in membrane-free extracts. The presence of specific, high-affinity insulin-like growth factor-I receptors in the skin and their upregulation at day 7 after wounding suggest that insulin-like growth factor-I plays an important role during wound healing.

A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers

Dopamine supersensitivity was induced by either the continuous daily release of 1.0 mg/kg haloperidol from controlled release polymers implanted subcutaneously in rats or by daily bolus injection. In vitro, these polymers were found to release haloperidol for more than 250 days. After implantation in vivo, supersensitivity was quantified by locomotor activity following apomorphine injection and specific [ 3H]spiroperidol binding to striatal synaptic membranes. Supersensitivity in rats with haloperidol implants was remarkably similar to that evoked by daily drug applications after 3 weeks without producing the detrimental daily sedations, typically seen after bolus administration. Furthermore, no difference in specific binding between both group was seen. A continuous delivery of haloperidol for 8 weeks also resulted in comparable denervation supersensitivity. Controlled release polymers may thus be a superior tool to induce denervation supersensitivity in a gradual, continuous fashion.

The serum insulin-like growth factor-II/mannose-6-phosphate receptor in normal and diabetic pregnancy

The extracellular domain of the insulin-like growth factor-II/mannose-6-phosphate (IGF-II/Man-6-P) receptor is present in the circulation of several species including man. The purpose of the present study was to establish whether this truncated receptor is present in higher concentrations in fetal sera compared with adult sera and whether the metabolic status of the individual alters serum concentrations of this protein. Nondiabetic and diabetic pregnant women were studied throughout gestation, and at term fetal cord sera were obtained. Levels of IGF-I increased throughout pregnancy in normal and diabetic women. IGF-II levels significantly increased during the third trimester in both groups and levels of IGF-I and IGF-II were significantly elevated in fetal cord samples from diabetic women only. Serum samples were gel-filtered on Sephadex G-200, and column fractions were assayed for binding of radiolabeled IGF-II and IGF-I. There was specific binding (SB) of IGF-II in the void volume fractions in all samplex examined. Normal women had 3% ± 0.5% SB, whereas in cord sera SB was 5% ± 0.7% and in pregnant sera 10% ± 2%. There was no difference in SB in fetal cord or pregnant samples from normal and diabetic women. In addition, there was a peak of binding activity of both IGF-I and -II in γ-globulin and postalbumin fractions of the columns in pregnant and nonpregnant women, but only in postalbumin fractions in fetal cord samples. Western blotting using a specific antiserum (no. 3637) against rat IGF-II/Man-6-P receptor was performed on aliquots of Sephadex G-200 void volume pools from all groups; a band of approximately 210 kd (without dithiothreitol) was seen. The band appeared to be more intense in pregnant women and to be increased in both the fetal cord samples and maternal samples from diabetic women. Based on binding and Western blotting, fetal cord samples had more receptor than nonpregnant normal women. When fetal cord, maternal, and adult nonpregnant sera Sephadex G-200 pools were assayed for IGF-II content by radioreceptor assay (RRA) after gel filtration in acid, only 1% to 2% of circulating IGF-II was associated with the truncated IGF-II/Man-6-P receptor in all cases. These data demonstrate that the extracellular domain (ecto-domain) of the IGF-II/Man-6-P receptor circulates in fetal cord serum and is elevated compared with that in normal adult women. Maternal concentration of the receptor is also increased in pregnancy. The ecto-domain of the IGF-II/Man-6-P receptor is not a significant carrier of the peptide and may reflect the increased levels of the peptide during pregnancy.

Ovine placental lactogen is a potent somatogen in the growth hormone (GH)-deficient rat: comparison of somatogenic activity with bovine GH.

The somatogenic effects of recombinant ovine placental lactogen (oPL) were investigated in the GH-deficient dwarf rat and compared to those of identical doses of recombinant bovine GH (bGH) in three independent studies. Both oPL and bGH treatments resulted in an increase (P less than 0.05) in body weight gain compared to that in saline controls, with oPL treatment being more potent than bGH (P less than 0.05). In promoting linear growth, oPL was more potent (P less than 0.05) than bGH in some instances. The nitrogen content of dry carcass matter was increased with oPL treatment compared to saline (P less than 0.05), with a nonsignificant increase in bGH-treated animals. Carcass fat was similarly reduced by both oPL and bGH treatment (P less than 0.05) compared to saline. Serum insulin-like growth factor-I (IGF-I) concentrations were increased significantly (P less than 0.05) by both oPL and bGH treatments, with a significantly greater effect of oPL suggested in one study. No increase in hepatic IGF-I mRNA was evident with either treatment, suggesting that the increase in serum IGF-I is due to posttranscriptional mechanisms. The expression of IGF-binding protein-3 hepatic mRNA was increased (P less than 0.05) with bGH treatment compared to that after saline treatment, but was unaffected by oPL treatment, indicating regulation by GH at the transcriptional level. The binding of [125I]bGH to hepatic membrane preparations demonstrated no difference in specific binding compared to that in saline controls. However, [125I]oPL specific binding was greater in oPL-treated animals (P less than 0.05). Animals treated with bGH had reduced (P less than 0.05) hepatic GH receptor mRNA compared to saline controls, but oPL treatment had no effect. Thus, oPL is a potent anabolic and lipolytic agent in the dwarf rat, exerting greater somatogenic effects on some parameters than bGH. Our data suggest differences in receptor binding and effects on GH receptor and IGF-binding protein-3 expression with these two treatments, raising the possibility of actions through different pathways or differential effects at the GH receptor level.

Effects of Prenatal Ethanol Exposure on Glucocorticoid Receptors in Rat Hippocampus

Animals exposed to ethanol in utero are typically hyperresponsive to stressors in adulthood as indicated by increased adrenocortical activation and/or deficits in response inhibition or recovery following stress. In the present study we reasoned that a deficit in feedback control of pituitary-adrenal activity might underlie this hyperresponsiveness in fetal ethanol-exposed (FEE) animals. Further, we hypothesized that a long-term decrease in hippocampal glucocorticoid receptor concentration, induced by prenatal ethanol exposure, might mediate such a deficit in pituitary-adrenal feedback regulation. Male and female Sprague-Dawley rats from prenatal ethanol (E), pair-fed (PF), and control (C) treatment groups were tested in adulthood for determination of cytosolic hippocampal glucocorticoid receptor binding. No significant differences in specific binding (Bmax) or binding affinity (Kd) of either type I or type II glucocorticoid receptors were found among animals from E, PF, and C conditions. There were, however, significant sex differences in receptor concentration and binding affinity; females showed significantly greater maximal binding and significantly lower binding affinity than males. These data do not support the hypothesis that prenatal ethanol exposure induces a long-term decrease in hippocampal glucocorticoid receptors in animals tested under basal nonstressed conditions. However, these data do not preclude the possibility that receptor binding capacity may be differentially affected in E, PF, and C animals during stress.

Binding and bioactivity of ovine and porcine prolactins in porcine mammary tissue

Differential binding of homologous and heterologous prolactin was investigated in porcine mammary tissue. Specific binding of ovine prolactin to porcine mammary membranes or tissue slices was significantly greater than specific binding of the homologous porcine prolactin. Ovine prolactin was also more potent than porcine prolactin in stimulating proliferation of Nb2 cells. In contrast, stimulation of glucose metabolism in porcine mammary explants by porcine prolactin was greater than that by ovine prolactin. Differences in specific binding were probably not due to damage during iodination, as low concentrations of iodinated prolactins were similar to unlabelled prolactins in their abilities to stimulate proliferation of Nb2 cells. Furthermore, electrophoretic analysis of medium from binding reactions suggested that differences in specific binding were not due to proteolytic cleavage of the homologous prolactin into large (greater than 10 kDa) fragments. These studies suggest that ovine prolactin either binds to sites in addition to the authentic lactogenic receptor in porcine mammary tissue or that a significantly higher affinity of ovine prolactin for the porcine lactogenic receptor has little effect on its biological activity.

Chronic ACTH treatment increases striatal dopamine D-2 receptor binding in developing rat brain

ACTH has been reported to decrease elevated levels of dopamine metabolites in the CSF of patients with infantile spasms who respond clinically to ACTH therapy. To study the possible role of dopamine receptors in the effect of ACTH, we treated rat pups for thirty days with 40 IU/kg subcutaneously of porcine ACTH or with normal saline. Using 10 nM 3H-spiperone and sulpiride to determine nonspecific binding, specific binding of D-2 receptors increased significantly (46%) in the striata of ACTH-treated rats when compared to controls. No significant difference in specific binding was found in the nucleus accumbens. Protein concentration was significantly decreased by ACTH treatment. Saturation studies will be necessary to determine if the increase in dopamine receptor binding induced by a high dose of ACTH represents a change in receptor density or affinity. The effect of lower clinical doses of ACTH on dopamine receptors warrants study.

3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease.

The specific binding of [3H]GBR-12935 to membranes prepared from human caudate nucleus is saturable (Bmax 1.36 +/- 0.18 pmol/mg protein), sodium dependent and of high affinity (KD 2.34 +/- 0.18 nM). Freezing of tissue from rat brain, or refrigeration followed by freezing, results in a small but significant (less than or equal to 20%) decrease in specific [3H]GBR-12935 binding when compared to the binding observed in fresh (nonfrozen) tissue, and this decrease may account, in part, for the differences in specific binding between rat and human brain membranes. Despite small differences in binding site density between fresh and frozen tissue there is a good correlation (r = 0.98; p less than 0.01) between the potencies of a series of drugs in displacing specific [3H]GBR-12935 binding to human caudate membranes and rat striatum as well as in inhibiting dopamine uptake in rat striatal synaptosomes (r = 0.96; p less than 0.01). The specific binding of [3H]GBR-12935 to membranes prepared from the caudate nuclei of patients with Parkinson's disease is decreased compared to membranes prepared from age- and sex-matched controls. These data suggest that [3H]GBR-12935 binds in a sodium-dependent fashion to the dopamine transport complex in human brain and that specific binding is decreased by a pathological degeneration of dopaminergic neurons to the caudate nucleus.

Sex Differences in [&lt;sup&gt;3&lt;/sup&gt;H]-Estradiol Binding in Brain and Pituitary after Acute Dopaminergic Treatment

Responses to estrogen differ between the sexes, yet sex differences in specific binding of estradiol (E2) to its receptor are not observed consistently. Dopaminergic treatment has been shown to increase binding of 3H-E2 in selected brain areas and anterior pituitary in the female rat, and the dopaminergic system is sexually differentiated. In order to determine whether or not dopaminergic stimulation might induce sex differences in 3H-E2 binding, male and female gonadectomized-adrenalectomized rats were pretreated either with bromocriptine, a dopamine agonist, or with diethyldithiocarbamate (DDC), an inhibitor of dopamine beta-hydroxylase. DDC was used in order to increase endogenous release of dopamine. After such acute dopaminergic treatment, specific binding of 3H-E2 in nuclear and extranuclear fractions of 6 brain areas and pituitary in vivo was determined 1 h after intravenous injection of 3H-E2 (1 microgram/kg body weight). Administration of either bromocriptine or DDC increased specific 3H-E2 binding to nuclear and extranuclear fractions of basal hypothalamus and anterior pituitary from female but not from male rats, thus inducing sex differences in binding in these two tissues. Bromocriptine also increased specific binding in the pineal in females. Total binding was increased in a crude membrane fraction (P2) from pituitary of female but not of male rats after administration of DDC, but the percent of extranuclear specific binding found in the P2 fraction was decreased after DDC in both males and females. The findings suggest that dopaminergic stimulation may induce sex differences in 3H-E2 binding by increasing binding in some brain areas and anterior pituitary in females but not in males.

Properties of hepatic binding sites for prolactin in ring doves ( Streptopelia risoria)

Specific binding of 125I-labeled ovine prolactin ( 125I-oPRL) was detected in crude membrane fractions prepared from ring dove ( Streptopelia risoria) liver homogenates. In characterization studies, specific binding was found to depend upon pH, incubation time, incubation temperature, and membrane protein concentration. Competitive inhibition of specifically bound 125I-oPRL was observed with human growth hormone, human and rat prolactin, and dove pituitary extract but not with turkey prolactin, human placental lactogen, and several nonlactogenic hormone preparations. Dove liver membranes showed high affinity ( K d = 3 × 10 −10 M) for binding to oPRL but had relatively low binding capacity ( B max < 20 fmol/mg protein). PRL binding activity in pooled liver fractions from breeding doves during early stages of incubation prior to crop sac growth did not differ markedly from that observed in doves sampled at the end of incubation when crop sac weight and serum PRL were elevated. However, binding activity was higher in pooled male liver fractions than in pooled female liver fractions at both reproductive stages. A two- to threefold increase in binding capacity was observed in pooled liver fractions from late-incubating doves following MgCl 2-induced binding site desaturation. The MgCl 2 treatment did not eliminate the differences in specific binding observed between male and female liver fraction pools, thus suggesting the possibility of sex-specific mechanisms of hepatic PRL binding site regulation in this species. It is concluded that the dove liver possesses specific binding sites for PRL with properties similar, but not identical, to those found in other vertebrate target tissues.

In vivo autoradiography: Visualization of stress-induced changes in opiate receptor occupancy in the rat brain

A method of in vivo autoradiography was utilized which allows the visualization of local changes in opiate receptor occupation in the intact rat brain. The method is based on the exclusion of [ 3H]diprenorphine binding in areas in which the release of endogenous opiate peptides is increased by behavioral manipulation. The technique lends itself to the use of film autoradiography, allowing the mapping of relative levels of functional receptor occupancy throughout the whole brain. Prolonged intermittent footshock and forced swims in cold water (two stress-inducing manipulations which are known to release endogenous opiates) were found to cause highly significant decreases in specific high-affinity [ 3H]diprenorphine binding, as measured by liquid scintillation counting. These changes were unaccompanied by corresponding changes in non-specific binding and were not related to local changes in blood flow. A prolonged nonstressful swim in warm water caused no changes in [ 3H]diprenorphine binding. The use of tritium-sensitive film autoradiography allowed the resolution of these decreases to the level of individual nuclei. Differences in specific binding were found to be greatest in the periaqueductal gray, the reticular formation, and in midline-intralaminar thalamic nuclei, all of which have been implicated in the modulation of pain sensation.

Characterization of hepatic low density lipoprotein binding and cholesterol metabolism in normal and homozygous familial hypercholesterolemic subjects.

Patients with familial hypercholesterolemia have elevated levels of plasma low density lipoproteins (LDL), increased hepatic synthesis of apolipoprotein B-containing lipoproteins, defective binding of low density lipoproteins to fibroblasts, and premature atherosclerosis. The role of a hepatic low density lipoprotein receptor in normal man and its importance in the pathogenesis of familial hypercholesterolemia have not been previously determined. In the present study, direct comparison was made of the binding of LDL to hepatic membranes from normal and receptor-negative homozygous familial hypercholesterolemic subjects. The effects of calcium, EDTA, and temperature on the binding of lipoproteins to the hepatic membranes were also evaluated. At 4 degrees C, no significant difference in specific binding of LDL to hepatic membranes from normal and familial hypercholesterolemic subjects was observed. At 37 degrees C, both total and specific binding of LDL were significantly reduced in patients with familial hypercholesterolemia. Hepatic membrane binding of LDL from the two patients homozygous for receptor-negative familial hypercholesterolemia was 53 and 59% of normal. The activity of the rate-limiting enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A reductase was normal; however, the total hepatic cholesterol and cholesteryl ester content was significantly increased from 53 to 129%. These results indicate that patients with familial hypercholesterolemia have a defect in the interaction of hepatic membranes with low density lipoproteins. This defect may lead to accelerated atherosclerosis by decreasing the cellular catabolism of LDL and enhancing the production of LDL, which is characteristic of patients homozygous for familial hypercholesterolemia.

Growth hormone binding to tissues of normal and stunted juvenile coho salmon, Oncorhynchus kisutch

The premature transfer of juvenile Coho salmon into seawater results in high mortality and a reduction of growth (stunting) of a significant portion of the population while the remainder of the salmon continue to grow normally. Binding studies were conducted with I25I‐labelled tilapia (Sarotherodon mossambicus) growth hormone (tGH) to determine if differences in specific binding of tGH existed in membrane preparations of tissues of stunted and normal coho salmon. Membrane preparations of both liver and gill of stunted salmon obtained from stocks in California, Washington and British Columbia and kidney membrane preparations obtained from stunted salmon in California exhibited deficiencies in 125I‐labelled tGH‐binding sites compared to corresponding membrane preparations of normal smolts. These results indicate that stunted coho salmon have a decreased ability to bind GH which may be reflected in perturbations in GH‐mediated processes.

Insulin-like growth factors I and II: some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum.

The insulin‐like growth factors I and II, two purified constituents of nonsuppressible insulinlike activity opf human serum, have nbeen compared with regard to some bniological actions in vitro and some receptor‐binding characteristics. In the presence of an excess of insulin‐antibodies the insulin‐like growth factors I and II (a) stimulate the net gas exchange in rat adipose tissue (fat pad assay) to a similar extent; (b) enhance 3‐O‐methylglucose transport, glucose oxidation and lipogenesis from glucose in rat adipocytes, with slight but significant differences in potency; (c) inhibit lipolysis in adipose tissue from fastedrefed rats, again with slight potency differences. In adipose toissue and adipocytes the biological activity of insulin‐like growth factors I and II is between 1/35 and 1/125 of that of insulin on a molar basis. Insulin‐like growth factors I and II are equally potent mitogens (stimulation of DNA‐synthesis and cell multiplication in cultured chick embryo fibroblasts). Insulin‐like growth factors I and II stimulate 35SO42‐ incorporation into rat costal cartilage with minor differences in potency. In rat adipocytes, insulin‐like growth factors I and II compete with insulin for binding to thje insulin receptor. However, their potencies in ‘displacing’125I‐labeled insulin are between 75 (for factor II) and 290 times (for factor I) lower than that of insulin. In addition, the factors I and II bind to binding sites specific for the factors and for which insulin does not compete. Considerable differences between factors I and II exist regarding their specific binding and their potencies in competing for binding of labeled factors I and II. In chick embryo fibroblasts and isolated chick embryo chondrocytes the insulin‐like growth factors I and II compete more or less equally for binding to a binding site specific for the factors and which appears to mediate their effects on cell growth and sulfation. Indsulin‐like growth factors I and II bind specifically to a partially purified carrier protein of human serum. Pronounced differences in specific binding and their potencies of competition are observed. Thus, the insulin‐like growth factors I and II, two structurally closely related polypeptides, display more or less similar activities in various biological systems in vitro. In all of these, their biological potency can be reasonably correlated with their potency of competition either for the insulin receptor (fat cells) or for a specific binding site (fibroblasts and cyhondrocytes). In some of the radioactive ligand systems, where the biological function of binding sites for insulin‐like growth factor is still unknown (such bindings sites are found in fat cells and on the serum carrier protein), clear cut differences between factors I and II are apparent.